Olema Financial Statements From 2010 to 2024

OLMA Stock  USD 10.12  0.40  4.12%   
Olema Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Olema Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Olema Pharmaceuticals financial statements helps investors assess Olema Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Olema Pharmaceuticals' valuation are summarized below:
Market Capitalization
579.9 M
Earnings Share
(2.28)
We have found one hundred eighteen available trending fundamental ratios for Olema Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Olema Pharmaceuticals recent market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.
Check Olema Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Olema Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 6 M, Interest Income of 6 M or Depreciation And Amortization of 445.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.63. Olema financial statements analysis is a perfect complement when working with Olema Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Olema Pharmaceuticals Correlation against competitors.
For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.

Olema Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets208 M276.9 M91.3 M
Slightly volatile
Other Current Liabilities17.7 M16.9 M4.1 M
Slightly volatile
Total Current Liabilities22.7 M21.6 M5.2 M
Slightly volatile
Property Plant And Equipment Net2.2 M3.3 M966.9 K
Slightly volatile
Accounts Payable2.8 M2.7 M575.1 K
Slightly volatile
Cash132.2 M68.5 M58.6 M
Slightly volatile
Non Current Assets Total11 M10.4 M2.5 M
Slightly volatile
Non Currrent Assets Other7.5 M7.2 M1.5 M
Slightly volatile
Other Assets0.951.023 M
Pretty Stable
Cash And Short Term Investments200.8 M261.8 M88.1 M
Slightly volatile
Common Stock Shares Outstanding40 M45.2 M24.7 M
Slightly volatile
Liabilities And Stockholders Equity208 M276.9 M91.3 M
Slightly volatile
Non Current Liabilities Total1.4 M1.4 M6.7 M
Slightly volatile
Other Current Assets2.8 MM1.2 M
Slightly volatile
Other Stockholder Equity379.6 M559.2 M163.5 M
Slightly volatile
Total Liabilities14.2 M23.1 M11.2 M
Slightly volatile
Property Plant And Equipment Gross2.4 M3.3 MM
Slightly volatile
Total Current Assets203.2 M266.5 M89.1 M
Slightly volatile
Common Stock2.8 KK1.7 K
Slightly volatile
Property Plant Equipment1.4 M1.7 M641.9 K
Slightly volatile
Common Stock Total Equity2.4 K2.7 K2.9 K
Slightly volatile
Short and Long Term Debt Total2.2 M2.4 M3.1 M
Slightly volatile
Current Deferred Revenue6.1 M6.9 M7.5 M
Slightly volatile
Net Receivables411.4 K673 K197.6 K
Slightly volatile
Capital Surpluse438.5 M469.6 M398.9 M
Slightly volatile
Non Current Liabilities Other1.6 M1.4 M2.2 M
Slightly volatile
Short Term Debt1.8 MM1.8 M
Slightly volatile

Olema Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest IncomeM5.7 M970.3 K
Slightly volatile
Depreciation And Amortization445.9 K377 K196.1 K
Slightly volatile
Selling General Administrative13.3 M18.8 M5.9 M
Slightly volatile
Other Operating Expenses57.1 M105 M25.7 M
Slightly volatile
Research Development43.8 M86.1 M19.7 M
Slightly volatile
Total Operating Expenses57.1 M105 M25.7 M
Slightly volatile
Reconciled Depreciation405.3 K386 K93.6 K
Slightly volatile
Cost Of Revenue358.1 K377 K277.2 K
Slightly volatile
Non Operating Income Net Other1.4 M2.5 M726.7 K
Slightly volatile
Selling And Marketing Expenses301.6 K339.3 K369.5 K
Slightly volatile

Olema Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings2.4 M3.6 M1.4 M
Slightly volatile
Begin Period Cash Flow22.5 M23.7 M26.8 M
Slightly volatile
Other Cashflows From Financing Activities3.5 M3.7 M21.7 M
Pretty Stable
Depreciation395.9 K377 K92.3 K
Slightly volatile
Total Cash From Financing Activities114.3 M133.4 M67.6 M
Slightly volatile
End Period Cash Flow82.1 M68.5 M37 M
Slightly volatile
Change To Netincome22.7 M21.7 M5.9 M
Slightly volatile
Dividends Paid2.5 M2.8 MM
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation1.111.174.5973
Slightly volatile
Payables Turnover0.130.13975.1781
Pretty Stable
Cash Per Share4.525.78622.6819
Slightly volatile
Days Payables Outstanding2.5 K2.6 K7.5 K
Very volatile
Income Quality0.910.86620.9199
Slightly volatile
Net Debt To EBITDA0.60.63222.2929
Pretty Stable
Current Ratio11.7112.326619.2246
Pretty Stable
Graham Number8.416.42265.4255
Slightly volatile
Debt To Equity0.00290.00350.0033
Pretty Stable
Capex Per Share0.01340.00820.0057
Slightly volatile
Interest Debt Per Share0.01280.01970.0086
Slightly volatile
Debt To Assets0.00270.00320.0031
Very volatile
Days Of Payables Outstanding2.5 K2.6 K7.5 K
Very volatile
Ebt Per Ebit1.10.92091.0354
Slightly volatile
Total Debt To Capitalization0.00290.00350.0033
Pretty Stable
Debt Equity Ratio0.00290.00350.0033
Pretty Stable
Quick Ratio11.7112.326619.2285
Pretty Stable
Net Income Per E B T1.11.131.035
Slightly volatile
Cash Ratio3.013.1716.9566
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.810.90.9851
Slightly volatile
Debt Ratio0.00270.00320.0031
Very volatile

Olema Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap404.2 M425.4 M1.5 B
Slightly volatile
Enterprise Value93.9 M98.9 M1.2 B
Slightly volatile

Olema Fundamental Market Drivers

Cash And Short Term Investments261.8 M

Olema Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Olema Pharmaceuticals Financial Statements

Olema Pharmaceuticals stakeholders use historical fundamental indicators, such as Olema Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Olema Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Olema Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Olema Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Olema Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue6.9 M6.1 M
Cost Of Revenue377 K358.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Olema Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Olema Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Olema Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Olema Pharmaceuticals Stock:
Check out the analysis of Olema Pharmaceuticals Correlation against competitors.
For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.28)
Return On Assets
(0.32)
Return On Equity
(0.52)
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.